Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 · New England Journal of Medicine · 4,204 citations
https://doi.org/10.1056/nejmoa1809615
R
Roberto Hegg
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
181
Papers
19.1K
Citations
40
h-index
58
i10-index
Roberto Hegg is an academic researcher from Universidade de São Paulo. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies. The author has an h-index of 40, co-authored 154 publications.
ORCID: 0000-0002-6453-8155Papers by this author
worksPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 · New England Journal of Medicine · 2,495 citations
https://doi.org/10.1056/nejmoa1113216
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
2020 · The Lancet · 1,743 citations
https://doi.org/10.1016/s0140-6736(20)32531-9
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
2020 · The Lancet · 1,021 citations
https://doi.org/10.1016/s0140-6736(20)31953-x
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · The Lancet Oncology · 865 citations
https://doi.org/10.1016/s1470-2045(19)30863-0
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
2021 · Annals of Oncology · 702 citations
https://doi.org/10.1016/j.annonc.2021.05.801
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat